wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28068643-C83D429A-7F88-4AB8-8368-44ECBA7BEA6C
Q28068643-C83D429A-7F88-4AB8-8368-44ECBA7BEA6C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28068643-C83D429A-7F88-4AB8-8368-44ECBA7BEA6C
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
P2860
Q28068643-C83D429A-7F88-4AB8-8368-44ECBA7BEA6C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28068643-C83D429A-7F88-4AB8-8368-44ECBA7BEA6C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f4c55b05dfcd5202fa5cb0b2f19c9777e64c8745
P2860
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.